JPMorgan raised the firm’s price target on Dyne Therapeutics to $39 from $25 and keeps an Overweight rating on the shares. The firm updated its model following Dyne’s release of new data from the Phase 1/2 ACHIEVE study for DYNE-101 in myotonic dystrophy type 1 and the Phase 1/2 DELIVER study for DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
- Dyne Therapeutics price target raised to $42 from $31 at Chardan
- Dyne Therapeutics files $300M common stock offering
- Dyne Therapeutics Announces Proposed Public Offering of Common Stock
- Dyne Therapeutics price target raised to $48 from $40 at Morgan Stanley